Importance of asymmetrical dimethylarginine in cardiovascular risk

Affiliations

Comment

P Vallance. Lancet. 2001 Dec.

. 2001 Dec;358(9299):2096-7.

doi: 10.1016/S0140-6736(01)07229-4.

¹ Centre for Clinical Pharmacology and Therapeutics, Department of Medicine, University College London, WC1E 6JJ, London, UK.

No abstract available

Comment on

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R. Zoccali C, et al. Lancet. 2001 Dec 22-29;358(9299):2113-7. doi: 10.1016/s0140-6736(01)07217-8. Lancet. 2001. PMID: 11784625
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.
Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Valkonen VP, et al. Lancet. 2001 Dec 22-29;358(9299):2127-8. doi: 10.1016/S0140-6736(01)07184-7. Lancet. 2001. PMID: 11784629